The Latin America, Middle East and Africa Gabapentin Market should witness market growth of 7.6% CAGR during the forecast period (2022-2028).
The market's growth is further fueled by awareness efforts like National Epilepsy Awareness Month in November, which work to increase understanding of the condition and encourage proactive measures to help control it. Also, more doctors nowadays are prescribing gabapentin rather than opioids to significantly reduce drug addiction. As a result, this is expected to increase the demand for medicine. The rising demand for gabapentin as a painkiller, particularly for neuropathic pain, is one of the main factors driving the market.
In addition, the increasing prevalence of chronic pain diseases like spinal cord injuries, shingles, and diabetic neuropathy, which are challenging to treat with traditional medicines, also increases the demand for gabapentin drugs. Therefore, many doctors are now prescribing gabapentin 'off-label'for both chronic andacute pain, even though the medication was initially created and used to treat epilepsy and seizures. Many doctors recommend it in place of opioids, and somerecommend it in addition to opioids.
Premised on the Global Burden of Disease (GBD) Studyresults, it has beenshown that non-communicable diseases (NCD)are emerging as the primary factorin causing death and disability in the Arab region. Years of life lost to early mortality and years spent with a disability are measured using disability-adjusted life years (DALYs), a useful tool for quantifying and ranking disease burden. Neurological illnesses constitute up to 3% of worldwide DALYs, and one-fourthof this category comprises epilepsy. Additionally, among the various causes of DALY, epilepsy was ranked at the 31st position in the region of North Africa and the Middle East. Therefore, the rising incidences of epilepsy and chronic pain in the region are the main factors accelerating the expansion of the gabapentin market in the region.
The Brazil market dominated the LAMEA Gabapentin Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $44.2 million by 2028. The Argentina market is experiencing a CAGR of 8.1% during (2022-2028). Additionally, The UAE market would display a CAGR of 7.3% during (2022-2028).
Based on Application, the market is segmented into Epilepsy, Restless Legs Syndrome, Neuropathic Pain, and Others. Based on Dosage Form, the market is segmented into Capsule, Tablet and Oral Solution. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy and Online Pharmacy. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Zydus Lifesciences Ltd., Glenmark Pharmaceuticals Limited, Pfizer, Inc., Sun Pharmaceutical Industries Ltd., Alkem Laboratories Ltd., Teva Pharmaceuticals Industries Ltd., Aurobindo Pharma Limited, Amneal Pharmaceuticals, Inc., Cipla Limited, and Apotex, Inc.
The market's growth is further fueled by awareness efforts like National Epilepsy Awareness Month in November, which work to increase understanding of the condition and encourage proactive measures to help control it. Also, more doctors nowadays are prescribing gabapentin rather than opioids to significantly reduce drug addiction. As a result, this is expected to increase the demand for medicine. The rising demand for gabapentin as a painkiller, particularly for neuropathic pain, is one of the main factors driving the market.
In addition, the increasing prevalence of chronic pain diseases like spinal cord injuries, shingles, and diabetic neuropathy, which are challenging to treat with traditional medicines, also increases the demand for gabapentin drugs. Therefore, many doctors are now prescribing gabapentin 'off-label'for both chronic andacute pain, even though the medication was initially created and used to treat epilepsy and seizures. Many doctors recommend it in place of opioids, and somerecommend it in addition to opioids.
Premised on the Global Burden of Disease (GBD) Studyresults, it has beenshown that non-communicable diseases (NCD)are emerging as the primary factorin causing death and disability in the Arab region. Years of life lost to early mortality and years spent with a disability are measured using disability-adjusted life years (DALYs), a useful tool for quantifying and ranking disease burden. Neurological illnesses constitute up to 3% of worldwide DALYs, and one-fourthof this category comprises epilepsy. Additionally, among the various causes of DALY, epilepsy was ranked at the 31st position in the region of North Africa and the Middle East. Therefore, the rising incidences of epilepsy and chronic pain in the region are the main factors accelerating the expansion of the gabapentin market in the region.
The Brazil market dominated the LAMEA Gabapentin Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $44.2 million by 2028. The Argentina market is experiencing a CAGR of 8.1% during (2022-2028). Additionally, The UAE market would display a CAGR of 7.3% during (2022-2028).
Based on Application, the market is segmented into Epilepsy, Restless Legs Syndrome, Neuropathic Pain, and Others. Based on Dosage Form, the market is segmented into Capsule, Tablet and Oral Solution. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy and Online Pharmacy. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Zydus Lifesciences Ltd., Glenmark Pharmaceuticals Limited, Pfizer, Inc., Sun Pharmaceutical Industries Ltd., Alkem Laboratories Ltd., Teva Pharmaceuticals Industries Ltd., Aurobindo Pharma Limited, Amneal Pharmaceuticals, Inc., Cipla Limited, and Apotex, Inc.
Scope of the Study
By Application
- Epilepsy
- Restless Legs Syndrome
- Neuropathic Pain
- Others
By Dosage Form
- Capsule
- Tablet
- Oral Solution
By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
By Country
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- Zydus Lifesciences Ltd.
- Glenmark Pharmaceuticals Limited
- Pfizer, Inc.
- Sun Pharmaceutical Industries Ltd.
- Alkem Laboratories Ltd.
- Teva Pharmaceuticals Industries Ltd.
- Aurobindo Pharma Limited
- Amneal Pharmaceuticals, Inc.
- Cipla Limited
- Apotex, Inc.
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. LAMEA Gabapentin Market by Application
Chapter 4. LAMEA Gabapentin Market by Dosage Form
Chapter 5. LAMEA Gabapentin Market by Distribution Channel
Chapter 6. LAMEA Gabapentin Market by Country
Chapter 7. Company Profiles
Companies Mentioned
- Zydus Lifesciences Ltd.
- Glenmark Pharmaceuticals Limited
- Pfizer, Inc.
- Sun Pharmaceutical Industries Ltd.
- Alkem Laboratories Ltd.
- Teva Pharmaceuticals Industries Ltd.
- Aurobindo Pharma Limited
- Amneal Pharmaceuticals, Inc.
- Cipla Limited
- Apotex, Inc.
Methodology
LOADING...
Related Reports
Gabapentin Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F
- Report
- 185 Pages
- Global
From
Gabapentin Market - Forecasts from 2024 to 2029
- Report
- 144 Pages
- Global
From
From
Gabapentin (CAS 60142-96-3) Global Market Research Report 2024
- Report
- 50 Pages
- Global
From
Gabapentin enacarbil (CAS 478296-72-9) Global Market Research Report 2024
- Report
- 50 Pages
- Global
From
About the Gabapentin Market
Gabapentin is a medication used to treat certain types of seizures and nerve pain. It is a central nervous system (CNS) drug, meaning it acts on the brain and spinal cord to produce its effects. It is used to treat epilepsy, neuropathic pain, hot flashes, and restless leg syndrome. It is also used off-label to treat anxiety and insomnia. Gabapentin is generally well-tolerated, but can cause side effects such as dizziness, drowsiness, and confusion. Gabapentin is available in both generic and Read more
This product is a market research report. Each license type allows a set number of users to access the report. Please select an option from the list below. This product is a market research report. This is a single user license, allowing one user access to the product. The product is a PDF. This product is a market research report. This is a site license, allowing all users within a given geographical location of your organization access to the product. The product is a PDF. This product is a market research report. This is an enterprise license, allowing all employees within your organization access to the product. The product is a PDF. 
